Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: A randomised, double-blind, placebo-controlled, mechanistic study

Diabetologia

Volumn 56, Issue 10, 2013, Pages 2153-2163

  Tripathy, Devjit ^a   Daniele, Giuseppe ^a,b   Fiorentino, Teresa V ^a,c   Perez Cadena, Zandra ^a   Chavez Velasquez, Alberto ^a   Kamath, Subhash ^a   Fanti, Paolo ^a   Jenkinson, Christopher ^a   Andreozzi, Francesco ^a,c   Federici, Massimo ^d   Gastaldelli, Amalia ^a,e   Defronzo, Ralph A ^a   Folli, Franco ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

Diabetes mellitus; Drug therapy; Glucose metabolism; Inflammation; Insulin secretion; Low dose pioglitazone; Muscle biopsy; TACE (TNF converting enzyme); TIMP 3 (Tissue inhibitor of metalloproteases 3)

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; FRACTALKINE; HEMOGLOBIN A1C; INTERLEUKIN 6; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; SULFONYLUREA; TISSUE INHIBITOR OF METALLOPROTEINASE 3; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME;

ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENZYME ACTIVITY; FLUORESCENCE ANALYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MUSCLE BIOPSY; MUSCLE LEVEL; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADAM PROTEINS; ADIPONECTIN; CHEMOKINE CCL2; CHEMOKINE CX3CL1; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INTERLEUKIN-6; MALE; MIDDLE AGED; MUSCLE, SKELETAL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THIAZOLIDINEDIONES; TISSUE INHIBITOR OF METALLOPROTEINASE-3; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84890120598     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-013-2976-z     Document Type: Article

References (42)

1. Del Prato S, Bonadonna RC, Bonora E et al (1993) Characterization of cellular defects of insulin action in type 2 (non-insulin-dependent) diabetes mellitus. J Clin Invest 91:484-494
2. Martin BC, Warram JH, Krolewski AS et al (1992) Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 340:925-929
3. Haffner SM, D'Agostino R Jr, Mykkänen L et al (1999) Insulin sensitivity in subjects with type 2 diabetes. Relationship to cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study. Diabetes Care 22:562-568
4. Khashper A, Gaspar T, Azencot M et al (2011) Visceral abdominal adipose tissue and coronary atherosclerosis in asymptomatic diabetics. Int J Cardiol 162:184-188
5. Preis SR, Hwang SJ, Coady S et al (2009) Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes in the Framingham Heart Study, 1950-2005. Circulation 119:1728-1735
6. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM (1996) IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance. Science 271:665-668
7. Austin RL, Rune A, Bouzakri K, Zierath JR, Krook A (2008) SiRNA-mediated reduction of inhibitor of nuclear factor-kappaB kinase prevents tumor necrosis factor-alpha-induced insulin resistance in human skeletal muscle. Diabetes 57:2066-2073
8. Federici M, Hribal ML, Menghini R et al (2005) Timp3 deficiency in insulin receptor-haploinsufficient mice promotes diabetes and vascular inflammation via increased TNF-alpha. J Clin Invest 115:3494-3505
9. Cefalu WT (2011) Fractalkine: a cellular link between adipose tissue inflammation and vascular pathologies. Diabetes 60:1380-1382
10. Miyazaki Y, Glass L, Triplitt C et al (2001) Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 44:2210-2219
11. DeFronzo RA, Tripathy D, Schwenke DC et al (2011) Pioglitazone for diabetes prevention in impaired glucose tolerance. N Engl J Med 364:1104-1115
12. Hanefeld M, Marx N, Pfützner A et al (2007) Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. J Am Coll Cardiol 49:290-297
13. Joner M, Farb A, Cheng Q et al (2007) Pioglitazone inhibits in-stent restenosis in atherosclerotic rabbits by targeting transforming growth factor-beta and MCP-1. Arterioscler Thromb Vasc Biol 27:182-189
14. Dormandy JA, Charbonnel B, Eckland DJ et al (2005) Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 366:1279-1289
15. Chiquette E, Ramirez G, Defronzo R (2004) A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104
16. Charbonnel B, Schernthaner G, Brunetti P et al (2005) Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes. Diabetologia 48:1093-1104
17. Balas B, Belfort R, Harrison SA et al (2007) Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. J Hepatol 47:565-570
18. Delea TE, Edelsberg JS, Hagiwara M, Oster G, Phillips LS (2003) Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 26:2983-2989
19. Kaul S, Bolger AF, Herrington D, Giugliano RP, Eckel RH (2010) Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College of Cardiology Foundation. Circulation 121:1868-1877
20. Karalliedde J, Buckingham R, Starkie M, Lorand D, Stewart M, Viberti G (2006) Effect of various diuretic treatments on rosiglitazone-induced fluid retention. J Am Soc Nephrol 17:3482-3490
21. Hovorka R, Soons PA, Young MA (1996) ISEC: a program to calculate insulin secretion. Comput Methods Programs Biomed 50:253-264
22. Cusi K, Maezono K, Osman A et al (2000) Insulin resistance differentially affects the PI 3-kinase- and MAP kinase-mediated signaling in human muscle. J Clin Invest 105:311-320
23. Monroy A, Kamath S, Chavez AO et al (2009) Impaired regulation of the TNF-alpha converting enzyme/tissue inhibitor of metalloproteinase 3 proteolytic system in skeletal muscle of obese type 2 diabetic patients: a new mechanism of insulin resistance in humans. Diabetologia 52:2169-2181
24. Jin G, Huang X, Black R et al (2002) A continuous fluorimetric assay for tumor necrosis factor-alpha converting enzyme. Anal Biochem 302:269-275
25. DeFronzo RA, Tobin JD, Andres R (1979) Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 237:E214-E223
26. Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA (2007) Thiazolidinediones improve beta-cell function in type 2 diabetic patients. Am J Physiol Endocrinol Metab 292:E871-E883
27. Inzucchi SE, Maggs DG, Spollett GR et al (1998) Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 338:867-872
28. Doehner W, Erdmann E, Cairns R et al (2011) Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population. Int J Cardiol 29:1-7
29. Aso Y, Hara K, Ozeki N et al (2009) Low-dose pioglitazone increases serum high molecular weight adiponectin and improves glycemic control in Japanese patients with poorly controlled type 2 diabetes. Diabetes Res Clin Pract 85:147-152
30. Kato T, Sawai Y, Kanayama H et al (2009) Comparative study of low-dose pioglitazone or metformin treatment in Japanese diabetic patients with metabolic syndrome. Exp Clin Endocrinol Diabetes 117:593-599
31. Bays H, Mandarino L, DeFronzo RA (2004) Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478
32. Pedersen BK, Febbraio MA (2012) Muscle, exercise and obesity: skeletal muscle as a secretory hormone. Nat Rev Endocrinol 8:457-465
33. Shoelson SE, Lee J, Goldfine AB (2006) Inflammation and insulin resistance. J Clin Invest 116:1793-1801
34. Goldfine AB, Fonseca V, Jablonski KA (2006) The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152:346-357
35. Fernàndez-Real JM, Pérez del Pulgar S, Luche E et al (2011) CD14 modulates inflammation-driven insulin resistance. Diabetes 60:2179-2186
36. Anfossi G, Russo I, Doronzo G, Pomero A, Trovati M (2010) Adipocytokines in atherothrombosis: focus on platelets and vascular smooth muscle cells. Mediators Inflamm. doi: 10.1155/2010/174341
37. Cardellini M, Perego L, D'Adamo M et al (2005) C-174G polymorphism in the promoter of the interleukin-6 gene is associated with insulin resistance. Diabetes Care 28:2007-2012
38. Bazan JF, Bacon KB, Hardiman G et al (1997) A new class of membrane-bound chemokine with a CX3C motif. Nature 385:640-644
39. Dragomir E, Manduteanu I, Calin M et al (2008) High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells. Thromb Haemost 100:1155-1165
40. Saederup N, Chan L, Lira SA, Charo IF (2008) Fractalkine deficiency markedly reduces macrophage accumulation and atherosclerotic lesion formation in CCR2-/- mice: evidence for independent chemokine functions in atherogenesis. Circulation 117:1642-1648
41. Wan Y, Evans RM (2010) Rosiglitazone activation of PPARgamma suppresses fractalkine signaling. J Mol Endocrinol 44:135-142
42. Yokoyama J, Sutoh N, Higuma T, Horiuchi D, Katoh C, Yokota T (2007) Efficacy and safety of low-dose pioglitazone after primary coronary angioplasty with the use of bare metal stent in patients with acute myocardial infarction and with type 2 diabetes mellitus or impaired glucose tolerance. Heart Vessels 22:146-151